Hudson Bay Capital Management
NBRV

Hudson Bay Capital Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Hudson Bay Capital Management’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-21,814
Closed -$55K – 851
2020
Q3 		$55K Hold
21,814
– – ﹤0.01% 522
2020
Q2 		$54K Buy
+21,814
New +$3.64M ﹤0.01% 474

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Hudson Bay Capital Management's NBRV Position: Q4 2020 in Review

Hudson Bay Capital Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2020, closing a stake of 21,814 shares — an estimated $55K sold.

Hudson Bay Capital Management first reported a position in NBRV in Q2 2020 and held it in 2 quarters. The position peaked at $55K in Q3 2020. 33 funds tracked by Wall St. Rank hold NBRV as of Q4 2020.

  • Hudson Bay Capital Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2020 after selling out during the quarter.
  • Hudson Bay Capital Management sold 21,814 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2020, an estimated $55K.
  • Hudson Bay Capital Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q2 2020 and held it in 2 quarters.
  • Hudson Bay Capital Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $55K in Q3 2020.
  • 33 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2020.

Based on Hudson Bay Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.